ACHV2:15 PMAchieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline TreatmentPresentation / Abstract • Phase 3ATS oral symposium Wed, May 20, 2026, 8:30 AM ETGachievelifesciences.com
ACHV7:05 AMAchieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharmaachievelifesciences.com
ACHV7:00 AMAchieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business UpdatesPresentation / Abstract • Phase 3achievelifesciences.com
ACHV8:30 AMAchieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026achievelifesciences.com
ACHV8:57 AMAchieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directorsachievelifesciences.com
ACHV8:53 AMAchieve Life Sciences Announces Up to $354 Million Private Placementachievelifesciences.com
ACHV8:00 AMAchieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutionsachievelifesciences.com
ACHV8:30 AMAchieve Life Sciences Announces Publication in Nicotine & Tobacco Research Linking Cytisinicline's Receptor Selectivity to Low Nausea Rates and Favorable Tolerabilityachievelifesciences.com
ACHV7:00 AMAchieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updatesachievelifesciences.com
ACHV8:30 AMAchieve Life Sciences to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on March 24, 2026achievelifesciences.com
ACHV8:00 AMAchieve Life Sciences Presents Data at SRNT Demonstrating Successful Cessation in Smokers with Extensive Prior Treatment Exposure; and on Participant Experience in the ORCA-OL StudyPresentation / Abstract • Phase 3achievelifesciences.com